BPaL(M) Regimen for the Treatment of MDR/RR-TB

Recruiting now · Phase 4

Conditions studied: Multidrug- and Rifampicin-resistant Tuberculosis

In brief

The objective of this study is to analyze the efficacy of a new regimen using Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin for 24 weeks or Bedaquiline, Pretomanid, Linezolid for 26 weeks for the treatment of MDR/RR-TB through the clinical trial.

Key facts

Study ID

NCT05381194

Run by

Asan Medical Center

People needed

80

Starts

2022-12-13

Expected to finish

2027-12-01

Last updated by the study team

2024-03-15

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 19 years old at enrolment
• Bodyweight over 35Kg
• If rifampicin resistance is confirmed through molecular or phenotypic drug susceptibility testing conducted on sputum or bronchoscopy specimens within 3 months of screening
• Chest radiological findings consistent with pulmonary tuberculosis

You may not qualify if…

• Uncontrolled DM
• Extrapulmonary TB that would require treatment longer than would be usual for pulmonary TB
• Less than 30 Karnofsky score at enrolment
• BMI less than 17
• Known severe allergy to any of the BPaLM regimen drugs
• Medical history of Glucose-galactose malabsorption, galactose intolerance, and Lapp lactase deficiency
• HIV-positive
• The QTcF interval exceeds 450 msec on the electrocardiogram at baseline
• Patients who are at risk of Torsade de Pointes due to underlying heart diseases such as heart failure or arrhythmia
• For women of childbearing potential if the pregnancy test is positive, women who are breastfeeding or planning to become pregnant within 6 months of discontinuation/termination of treatment during the study, or who do not want contraception (i.e., oral and subcutaneous hormonal contraceptives, condoms, diaphragms, intrauterine device, or use of appropriate contraceptive methods including abstinence)
• Note: Double contraception (e.g., when a male uses a barrier contraceptive method such as a condom, a female partner uses a hormonal contraceptive or an additional contraceptive method such as an intrauterine device) is required while taking the study drug and up to 6 months after stopping/terminating the study drug. In particular, taking the study drug may affect the efficacy of hormonal contraceptives, and even if you are using only barrier contraception at the same time with your partner, you cannot be sure of preventing pregnancy, so it is necessary to maintain double contraception.
• Men who plan to become pregnant during the study period or within 6 months of discontinuation/termination of treatment, or who do not wish to use double contraception or abstinence during this period.
• Patients who have Grade 3 or 4 or higher peripheral neuritis, or Grade 1 or 2 with a high probability of progression to peripheral neuritis,
• Current use of monoamine oxidase Inhibitor or used 2 weeks before treatment
• Use of serotonergic antidepressant within 3 days of treatment
• Any contraindication that may affect QTc interval (amiodarone, chloroquine, chlorpromazine, clarithromycin, haloperidol, etc.)
• Any contraindication that may cause myelosuppression
• Taking drugs that affect the cytochrome P450 enzyme within 30 days (quinidine, tyramine, ketoconazole, fluconazole, testosterone, quinine, gestodene, metyrapone, phenelzine, doxorubicin, troleandomycin, cyclobenzaprine, erythromycin, cocaine, furafylline, cimetidine, dextromethorphan, etc.)
• Previously treated with Bedaquiline or Linezolid for more than 4 weeks
• Abnormal value of a blood test at baseline:
• Hypokalemia, Hemoglobin < 8.0 g/dL, Platelet < 75,000/mm3, ANC < 1000/mm3
• AST or ALT > 3 X ULN, Total bilirubin >2.0 X ULN, Albumin < 3.2 mg/dL
• Serum creatinine > 2 X ULN, Serum calcium < LLN, Serum magnesium < LLN

Where it is running

• Asan Medical Center — Seoul, Songpa-gu, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.